Alumis Inc.
ALMS
Rangering i aksjer
#10084
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aksjekurs
$6.58
Markedsverdi
$851.58M
Endring (1 dag)
3.77%
Endring (1 år)
189.83%
Land
US
Handel Alumis Inc. (ALMS)
Kategori
Healthcare
Antall utestående aksjer for Alumis Inc. (ALMS)
Antall utestående aksjer per March 2025: 100.68M
Ifølge Alumis Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 100.68M. Ved slutten av December 2023 hadde selskapet 70.25M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Alumis Inc. (ALMS) fra 2021 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 100.68M | 1.39% |
| 2024 | 99.30M | 41.35% |
| 2023 | 70.25M | 243.63% |
| 2022 | 20.44M | 0.00% |
| 2021 | 20.44M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 152.18% |
US
|
|
| 396.00M | 293.32% |
US
|
|
| 478.91M | 375.68% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -38.23% |
NL
|
